All News

Therapeutic mammoplasty with contralateral symmetrization showed low long-term local recurrence in early breast cancer, with failure to complete adjuvant therapy as the strongest modifiable predictor of recurrence.

Guilherme Perini, MD, PhD, explained the rationale behind the KEYFORM-008 trial, exploring how targeting LAG3 can reverse checkpoint inhibitor resistance.

ASCO Breakthrough 2026 spotlights ADCs, CAR-T, ctDNA-guided colorectal care and menin inhibitors driving precision cancer treatment.

Experts map DLBCL CAR‑T from early referral and bridging therapy to managing CRS, ICANS, and survivorship challenges in community practice.

The tentative approval covers enzalutamide tablets in 4 doses—40 mg, 80 mg, 120 mg, and 160 mg—as a generic equivalent to the reference product.

The CHMP’s recommendation for approving teclistamab plus daratumumab in this multiple myeloma population is based on data from the phase 3 MajesTEC-3 study.

Nicholas Hornstein, MD, PhD discusses ctDNA in colorectal cancer, the INTERCEPT-TT trial, building Northwell's GI oncology program, and what better drugs will look like.

In this single-center retrospective series of 45 patients with locally advanced breast cancer, preoperative 5-fraction ultra-hypofractionated radiotherapy yielded favorable clinical response in 46.6% and clinical downstaging in 92.9% of evaluable surgical cases.

This narrative review synthesizes evidence on breast cancer–related lymphedema prevention and management, finding that surgical mitigation strategies and coordinated radiation planning within multidisciplinary pathways reduce BCRL risk and improve survivorship outcomes.

Guilherme Fleury Perini, MD, PhD, discussed KEYFORM-008 findings on favezelimab/pembrolizumab vs chemotherapy in PD-1–refractory classic Hodgkin lymphoma.

INELDA-certified death doula Kim Stravers shares a detailed account of supporting a patient with pancreatic cancer and Lynch syndrome.

Findings from the phase 2 MOR208C203 trial and phase 1b/2 INCMOR 0208-102 trial support the Japanese regulatory decision for tafasitamab in DLBCL.

Preliminary data from the phase 1/2 TARGET-D 101 trial showed a manageable safety profile for VS-7375 across KRAS G12D–mutated solid tumors.

Sherry Shen, MD, shares retrospective data on how GLP-1s influence overall survival and safety outcomes among patients with breast cancer.

Experts highlight how updates on the EV-302 and RAMPART studies may influence care across different bladder and kidney cancer populations.

In this retrospective cohort of 99 patients, PMRT-related post-reconstruction complications occurred in 25%, with chemotherapy receipt associated with significantly lower complication risk and no association found for BMI, cancer stage, or reconstruction type.

In an external blinded validation of 426 women with HR-positive, HER2-negative IBC at Royal Melbourne Hospital, a multi-omic test stratified patients by LRR risk and RT benefit, identifying subgroups who could safely omit RT and those with elevated risk who benefited significantly.

Results from the phase 3 ASCENT-03 and ASCENT-04 trials supported the FDA approval across both locally advanced or metastatic TNBC indications.

Retrospective data showed that GLP-1 receptor agonist use was associated with a 51% reduction in colorectal cancer odds among patients with inflammatory bowel disease.

Findings from the phase 3 PATINA trial support the FDA approval of palbociclib plus trastuzumab with or without pertuzumab in this breast cancer population.

Findings from the phase 3 EV-303 trial evaluating the enfortumab-based regimen vs surgery alone in this MIBC group supported the regulatory decision.

Sherry Shen, MD, broke down early data from MSK evaluating the role GLP-1s play in survival and helping to manage long-term outcomes in breast cancer.

The latest conversation in RadOnc on the Run explores patient and provider considerations for navigating cancer diagnosis, treatment, and recovery.

PREDICT II is a prospective 30-site observational registry enrolling 3000 women with DCIS to evaluate how a 7-gene biosignature (DCISionRT) impacts treatment recommendations for surgery, radiation, and hormonal therapy.

In this randomized trial, adding a pictorial COPE photo guide to standard verbal counseling for breast cancer patients receiving adjuvant RT led to the only statistically significant improvement in post-treatment skin change scores, with modest non-significant trends toward reduced anxiety.

An informed multiplex PCR circulating tumor DNA–based molecular residual disease test could inform adjuvant treatment following cystectomy.

Investigators will share detailed results from the phase 3 SigVie-002 trial assessing sigvotatug vedotin in NSCLC at a future medical meeting.

Zanzalintinib plus atezolizumab did not elicit a statistically significant overall survival advantage over regorafenib in patients with non–MSI-H mCRC without active liver metastases.

Sherry Shen, MD, explained the compounding factors behind weight gain during breast cancer care and why managing cardiometabolic health is vital for survival.

Kim Stravers, an INELDA-certified death doula and educator, explains how end-of-life doulas provide nonmedical emotional, practical, and relational support to patients with cancer and their families.